Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-5f56664f6-2gss9 Total loading time: 0 Render date: 2025-05-07T10:58:45.275Z Has data issue: false hasContentIssue false

22 - Hematopoietic stem cell and natural killer cell transplantation

from Section 3 - Evaluation and treatment

Published online by Cambridge University Press:  05 April 2013

By
Wing Leung  and
Michael A. Pulsipher
Edited by
Ching-Hon Pui
Ching-Hon Pui
Affiliation:
St Jude's Children's Research Hospital
Get access

Summary

Introduction

Blood and bone marrow (BM) transplantation (BMT) or hematopoietic stem cell transplantation (HSCT) are procedures that utilize autologous or allogeneic cells to reconstitute a hematopoietic system, after chemotherapy with or without total body irradiation (TBI) to treat cancer intensively or suppress the recipient immunologically to prevent rejection. When used to treat leukemia, the intent of most transplantation approaches in pediatrics is to decrease relapse by using very high doses of cancer therapy to overcome partially resistant cancer cells. Standard high-dose “preparative” regimens (myeloablative regimens) cause irreversible BM failure unless there is “rescue” by the stem cell infusion. While the intensity of therapy alone is sufficient to cure some resistant malignancies, allogeneic transplantation has been noted to add an immunotherapeutic benefit, termed the graft-versus-leukemia (GVL) effect. Sources of hematopoietic stem cells currently used for HSCT include BM, peripheral blood stem cells (PBSC), and umbilical cord blood (CB).

Because intensive therapy associated with the transplantation process can result in organ damage, susceptibility to life-threatening infection, late effects such as growth delay, and immunologic complications such as graft-versus-host disease (GVHD), it is reserved for cancers not curable with standard chemotherapeutic approaches or where there is a significant survival advantage over less intense therapies. Traditional indications for HSCT in leukemia include first or subsequent relapse and the very highest risk subclassifications of leukemias in first remission. As chemotherapy and transplantation outcomes improve, and as more precise definitions of disease risk are discovered, indications for transplantation change. Therefore, careful dialogue between oncologists and transplant physicians should occur early in the course of therapy for high-risk leukemias to determine when or if a transplantation procedure is indicated.

Type
Chapter
Information
Childhood Leukemias , pp. 527 - 548
Publisher: Cambridge University Press
Print publication year: 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Blume, KG, Krance, RA. The evaluation and counseling of candidates for hematopoietic cell transplantation. In Appelbaum, FR, Forman, SJ, Negrin, RS, et al. (eds.) Thomas' Hematopoietic Cell Transplantation, 4th edn. Malden, MA: Blackwell, 2009:443–460.CrossRefGoogle Scholar
Deeg, HJ, Seidel, K, Bruemmer, B, et al. Impact of patient weight on non-relapse mortality after marrow transplantation. Bone Marrow Transplant 1995;15:461–468.Google ScholarPubMed
Sorror, M, Storer, B, Sandmaier, BM, et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 2008;112:1992–2001.CrossRefGoogle ScholarPubMed
Sorror, ML, Maris, MB, Storb, R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106:2912–2919.CrossRefGoogle ScholarPubMed
Xun, CQ, McSweeney, PA, Boeckh, M, et al. Successful nonmyeloablative allogeneic hematopoietic stem cell transplant in an acute leukemia patient with chemotherapy-induced marrow aplasia and progressive pulmonary aspergillosis. Blood 1999;94:3273–3276.Google Scholar
Hermann, S, Klein, SA, Jacobi, V, et al. Older patients with high-risk fungal infections can be successfully allografted using non-myeloablative conditioning in combination with intensified supportive care regimens. Br J Haematol 2001;113:446–454.CrossRefGoogle ScholarPubMed
Gassas, A, Ishaqi, MK, Afzal, S, et al. Outcome of haematopoietic stem cell transplantation for paediatric acute lymphoblastic leukaemia in third complete remission: a vital role for graft-versus-host-disease/graft-versus-leukaemia effect in survival. Br J Haematol 2008;140:86–89.Google ScholarPubMed
Radich, JP, Gooley, T, Sanders, JE, et al. Second allogeneic transplantation after failure of first autologous transplantation. Biol Blood Marrow Transplant 2000;6:272–279.CrossRefGoogle ScholarPubMed
Radich, JP, Sanders, JE, Buckner, CD, et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol 1993;11:304–313.CrossRefGoogle ScholarPubMed
Woolfrey, AE, Anasetti, C, Storer, B, et al. Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. Blood 2002;99:2002–2008.CrossRefGoogle ScholarPubMed
Bradley, MB, Satwani, P, Baldinger, L, et al. Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases. Bone Marrow Transplant 2007;40:621–631.CrossRefGoogle ScholarPubMed
Claviez, A, Klingebiel, T, Beyer, J, et al. Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin's disease. Ann Hematol 2004;83:237–241.CrossRefGoogle ScholarPubMed
Del Toro, G, Satwani, P, Harrison, L, et al. A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients. Bone Marrow Transplant 2004;33:613–622.CrossRefGoogle ScholarPubMed
Pulsipher, MA, Boucher, KM, Wall, D, et al. Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313. Blood 2009;114:1429–1436.CrossRefGoogle ScholarPubMed
Pulsipher, MA, Woolfrey, A. Nonmyeloablative transplantation in children. Current status and future prospects. Hematol Oncol Clin North Am 2001;15:809–34, vii--viii.CrossRefGoogle ScholarPubMed
Roman, E, Cooney, E, Harrison, L, et al. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. Clin Cancer Res 2005;11:7164s–7170s.CrossRefGoogle ScholarPubMed
Flomenberg, N, Baxter-Lowe, LA, Confer, D, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004;104:1923–1930.CrossRefGoogle Scholar
Lee, SJ, Klein, J, Haagenson, M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007;110:4576–4583.CrossRefGoogle ScholarPubMed
Uhrberg, M.The KIR gene family: life in the fast lane of evolution. Eur J Immunol 2005;35:10–15.CrossRefGoogle Scholar
Petersdorf, EW, Malkki, M, Gooley, TA, et al. MHC haplotype matching for unrelated hematopoietic cell transplantation. PLoS Med 2007;4:e8.CrossRefGoogle ScholarPubMed
Ruggeri, L, Mancusi, A, Capanni, M, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007;110:433–440.CrossRefGoogle ScholarPubMed
Leung, W, Iyengar, R, Turner, V, et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004;172:644–650.CrossRefGoogle ScholarPubMed
Willemze, R, Rodrigues, CA, Labopin, M, et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia 2009;23:492–500.CrossRefGoogle ScholarPubMed
Cooley, S, Trachtenberg, E, Bergemann, TL, et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009;113:726–732.CrossRefGoogle Scholar
Leung, W, Iyengar, R, Triplett, B, et al. Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol 2005;174:6540–6545.CrossRefGoogle ScholarPubMed
Bari, R, Bell, T, Leung, WH, et al. Significant functional heterogeneity among KIR2DL1 alleles and a pivotal role of arginine 245. Blood 2009;114:5182–5190.CrossRefGoogle Scholar
Confer, DL, Abress, LK, Navarro, W, et al. Selection of adult unrelated hematopoietic stem cell donors: beyond HLA. Biol Blood Marrow Transplant 2010;16(1 Suppl):S8--S11.CrossRefGoogle ScholarPubMed
Bensinger, WI, Martin, PJ, Storer, B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001;344:175–181.CrossRefGoogle ScholarPubMed
Champlin, RE, Schmitz, N, Horowitz, MM, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000;95:3702–3709.Google Scholar
Broxmeyer, HE, Douglas, GW, Hangoc, G, et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci USA 1989;86:3828–3832.CrossRefGoogle ScholarPubMed
Gluckman, E, Broxmeyer, HA, Auerbach, AD, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 1989;321:1174–1178.CrossRefGoogle Scholar
Pulsipher, MA, Levine, JE, Hayashi, RJ, et al. Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: the pediatric blood and marrow transplant consortium experience (PBMTC) 1996–2003. Bone Marrow Transplant 2005;35:361–367.CrossRefGoogle ScholarPubMed
Pulsipher, MA, Nagler, A, Iannone, R, et al. Weighing the risks of G-CSF administration, leukopheresis, and standard marrow harvest: ethical and safety considerations for normal pediatric hematopoietic cell donors. Pediatr Blood Cancer 2006;46:422–433.CrossRefGoogle ScholarPubMed
Watanabe, T, Takaue, Y, Kawano, Y, et al. HLA-identical sibling peripheral blood stem cell transplantation in children and adolescents. Biol Blood Marrow Transplant 2002;8:26–31.CrossRefGoogle ScholarPubMed
Diaz, MA, Gonzalez-Vicent, M, Gonzalez, ME, et al. Long-term outcome of allogeneic PBSC transplantation in pediatric patients with hematological malignancies: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON) and the Spanish Group for Allogeneic Peripheral Blood Transplantation (GETH). Bone Marrow Transplant 2005;36:781–785.CrossRefGoogle Scholar
Levine, JE, Wiley, J, Kletzel, M, et al. Cytokine-mobilized allogeneic peripheral blood stem cell transplants in children result in rapid engraftment and a high incidence of chronic GVHD. Bone Marrow Transplant 2000;25:13–18.CrossRefGoogle Scholar
Eapen, M, Horowitz, MM, Klein, JP, et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 2004;22:4872–4880.CrossRefGoogle ScholarPubMed
Frangoul, H, Nemecek, ER, Billheimer, D, et al. A prospective study of G-CSF primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium (PBMTC) study. Blood 2007;110:4584–4587.CrossRefGoogle ScholarPubMed
Ballen, KK, King, RJ, Chitphakdithai, P, et al. The national marrow donor program 20 years of unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008;14:2–7.CrossRefGoogle ScholarPubMed
Eapen, M, Logan, BR, Confer, DL, et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant 2007;13:1461–1468.CrossRefGoogle ScholarPubMed
Remberger, M, Ringden, O, Blau, IW, et al. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 2001;98:1739–1745.CrossRefGoogle ScholarPubMed
Bray, RA, Hurley, CK, Kamani, NR, et al. National marrow donor program HLA matching guidelines for unrelated adult donor hematopoietic cell transplants. Biol Blood Marrow Transplant 2008;14:45–53.CrossRefGoogle ScholarPubMed
Kollman, C, Abella, E, Baitty, RL, et al. Assessment of optimal size and composition of the US National Registry of hematopoietic stem cell donors. Transplantation 2004;78:89–95.CrossRefGoogle Scholar
Barker, JN, Rocha, V, Scaradavou, A. Optimizing unrelated donor cord blood transplantation. Biol Blood Marrow Transplant 2008;15:154–161.CrossRefGoogle Scholar
Eapen, M, Rubinstein, P, Zhang, MJ, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 2007;369:1947–1954.CrossRefGoogle ScholarPubMed
Barker, JN, Scaradavou, A, Stevens, CE. Combined effect of total nucleated cell dose and HLA-match on transplant outcome in 1061 cord blood recipients with hematological malignancies. Blood 2010;115:1843–1849.CrossRefGoogle Scholar
Bortin, MM, Buckner, CD. Major complications of marrow harvesting for transplantation. Exp Hematol 1983;11:916–921.Google ScholarPubMed
Buckner, CD, Clift, RA, Sanders, JE, et al. Marrow harvesting from normal donors. Blood 1984;64:630–634.Google ScholarPubMed
Hill, HF, Chapman, CR, Jackson, TL, et al. Assessment and management of donor pain following marrow harvest for allogeneic bone marrow transplantation. Bone Marrow Transplant 1989;4:157–161.Google ScholarPubMed
Chan, KW, Gajewski, JL, Supkis, D., et al. Use of minors as bone marrow donors: current attitude and management. A survey of 56 pediatric transplantation centers. J Pediatr 1996;128:644–648.CrossRefGoogle ScholarPubMed
Sanders, J, Buckner, CD, Bensinger, WI, et al. Experience with marrow harvesting from donors less than two years of age. Bone Marrow Transplant 1987;2:45–50.Google Scholar
Urban, C, Weber, G, Slavc, I, et al. Anesthetic management of marrow harvesting from a 7-week-old premature baby. Bone Marrow Transplant 1990;6:443–444.Google ScholarPubMed
van Walraven, SM, Nicoloso-de Faveri, G, Axdorph-Nygell, UA, et al. Family donor care management: principles and recommendations. Bone Marrow Transplant 2010;45:1269–1273.CrossRefGoogle ScholarPubMed
de La Rubia, J, Diaz, MA, Verdeguer, A, et al. Donor age-related differences in PBPC mobilization with rHuG-CSF. Transfusion 2001;41:201–205.CrossRefGoogle ScholarPubMed
Kawano, Y, Takaue, Y, Watanabe, T, et al. Efficacy of the mobilization of peripheral blood stem cells by granulocyte colony-stimulating factor in pediatric donors. Cancer Res 1999;59:3321–3324.Google ScholarPubMed
Confer, DL, Miller, JP. Long-term safety of filgrastim (rhG-CSF) administration. Br J Haematol 2007;137:77–78; author reply 79–80.CrossRefGoogle ScholarPubMed
Pulsipher, MA, Chitphakdithai, P, Miller, JP, et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood 2009;113:3604–3611.CrossRefGoogle ScholarPubMed
Davies, SM, Ramsay, NK, Klein, JP, et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol 2000;18:340–347.CrossRefGoogle ScholarPubMed
Eapen, M, Raetz, E, Zhang, MJ, et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood 2006;107:4961–4967.CrossRefGoogle ScholarPubMed
Wall, DA, Carter, SL, Kernan, NA, et al. Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience. Biol Blood Marrow Transplant 2005;11:637–646.CrossRefGoogle ScholarPubMed
Sanders, JE, Im, HJ, Hoffmeister, PA, et al. Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia. Blood 2005;105:3749–3756.CrossRefGoogle ScholarPubMed
Neudorf, S, Sanders, J, Kobrinsky, N, et al. Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. Blood 2004;103:3655–3661.CrossRefGoogle ScholarPubMed
Sisler, IY, Koehler, E, Koyama, T, et al. Impact of conditioning regimen in allogeneic hematopoietic stem cell transplantation for children with acute myelogenous leukemia beyond first complete remission: a pediatric blood and marrow transplant consortium (PBMTC) study. Biol Blood Marrow Transplant 2009;15:1620–1627.CrossRefGoogle ScholarPubMed
Giralt, S, Estey, E, Albitar, M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89:4531–4536.Google ScholarPubMed
Slavin, S, Nagler, A, Naparstek, E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756–763.Google ScholarPubMed
Storb, R, Yu, C, Sandmaier, BM, et al. Mixed hematopoietic chimerism after marrow allografts. Transplantation in the ambulatory care setting. Ann N Y Acad Sci 1999;872:372–375; discussion 375–376.CrossRefGoogle ScholarPubMed
Gomez-Almaguer, D, Ruiz-Arguelles, GJ, del Tarin-Arzaga, LC, et al. Reduced-intensity stem cell transplantation in children and adolescents: the Mexican experience. Biol Blood Marrow Transplant 2003;9:157–161.CrossRefGoogle ScholarPubMed
Champlin, RE, Passweg, JR, Zhang, MJ, et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood 2000;95:3996–4003.Google ScholarPubMed
Gaynon, PS, Trigg, ME, Heerema, NA, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983–1995. Leukemia 2000;14:2223–2233.CrossRefGoogle ScholarPubMed
Pui, CH, Evans, WE. Acute lymphoblastic leukemia. N Engl J Med 1998;339:605–615.CrossRefGoogle ScholarPubMed
Schrappe, M, Reiter, A, Zimmermann, M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin–Frankfurt–Münster. Leukemia 2000;14:2205–2222.CrossRefGoogle Scholar
Hahn, T, Wall, D, Camitta, B, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review. Biol Blood Marrow Transplant 2005;11:823–861.CrossRefGoogle ScholarPubMed
Arico, M, Valsecchi, MG, Camitta, B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000;342:998–1006.CrossRefGoogle ScholarPubMed
Nachman, JB, Heerema, NA, Sather, H, et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 2007;110:1112–1115.CrossRefGoogle ScholarPubMed
Silverman, LB, Gelber, RD, Young, ML, et al. Induction failure in acute lymphoblastic leukemia of childhood. Cancer 1999;85:1395–1404.3.0.CO;2-2>CrossRefGoogle ScholarPubMed
Schultz, KR, Pullen, DJ, Sather, HN, et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood 2007;109:926–935.CrossRefGoogle Scholar
Schultz, KR, Bowman, WP, Aledo, A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children's Oncology Group study. J Clin Oncol 2009;27:5175–5181.CrossRefGoogle ScholarPubMed
Oudot, C, Auclerc, MF, Levy, V, et al. Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study. J Clin Oncol 2008;26:1496–1503.CrossRefGoogle ScholarPubMed
Pulsipher, MA, Wall, DA, Grimley, M, et al. A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). Br J Haematol 2009;147:691–699.CrossRefGoogle Scholar
Satwani, P, Sather, H, Ozkaynak, F, et al. Allogeneic bone marrow transplantation in first remission for children with ultra-high-risk features of acute lymphoblastic leukemia: a Children's Oncology Group study report. Biol Blood Marrow Transplant 2007;13:218–227.CrossRefGoogle ScholarPubMed
Schrauder, A, von Stackelberg, A, Schrappe, M, et al. Allogeneic hematopoietic SCT in children with ALL: current concepts of ongoing prospective SCT trials. Bone Marrow Transplant 2008;41(Suppl 2):S71–S74.CrossRefGoogle ScholarPubMed
Tomizawa, D, Koh, K, Sato, T, et al. Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. Leukemia 2007;21:2258–2263.CrossRefGoogle ScholarPubMed
van der Linden, MH, Valsecchi, MG, de Lorenzo, P, et al. Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol. Blood 2009;114:3764–3768.CrossRefGoogle ScholarPubMed
Kosaka, Y, Koh, K, Kinukawa, N, et al. Infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantation. Blood 2004;104:3527–3534.CrossRefGoogle ScholarPubMed
Hilden, JM, Dinndorf, PA, Meerbaum, SO, et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood 2006;108:441–451.CrossRefGoogle ScholarPubMed
Pieters, R, Schrappe, M, de Lorenzo, P, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007;370:240–250.CrossRefGoogle Scholar
Borowitz, MJ, Devidas, M, Hunger, SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 2008;111:5477–5485.CrossRefGoogle ScholarPubMed
Coustan-Smith, E, Behm, FG, Sanchez, J, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998;351:550–554.CrossRefGoogle ScholarPubMed
Coustan-Smith, E, Sancho, J, Behm, FG, et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 2002;100:52–58.CrossRefGoogle ScholarPubMed
Gaynon, PS, Qu, RP, Chappell, RJ, et al. Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse – the Children's Cancer Group Experience. Cancer 1998;82:1387–1395.3.0.CO;2-1>CrossRefGoogle ScholarPubMed
Lawson, SE, Harrison, G, Richards, S, et al. The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the medical research council UKALLR1 study. Br J Haematol 2000;108:531–543.CrossRefGoogle ScholarPubMed
Kolb, EA, Steinherz, PG. A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia. Leukemia 2003;17:1967–1972.CrossRefGoogle ScholarPubMed
Barrett, AJ, Horowitz, MM, Pollock, BH, et al. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med 1994;331:1253–1258.CrossRefGoogle Scholar
Locatelli, F, Zecca, M, Messina, C, et al. Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors. Leukemia 2002;16:2228–2237.CrossRefGoogle ScholarPubMed
Bleakley, M, Lau, L, Shaw, PJ, et al. Bone marrow transplantation for paediatric AML in first remission: a systematic review and meta-analysis. Bone Marrow Transplant 2002;29:843–852.CrossRefGoogle ScholarPubMed
Boulad, F, Steinherz, P, Reyes, B, et al. Allogeneic bone marrow transplantation versus chemotherapy for the treatment of childhood acute lymphoblastic leukemia in second remission: a single-institution study. J Clin Oncol 1999;17:197–207.CrossRefGoogle ScholarPubMed
Ritchey, AK, Pollock, BH, Lauer, SJ, et al. Improved survival of children with isolated CNS relapse of acute lymphoblastic leukemia: a pediatric oncology group study. J Clin Oncol 1999;17:3745–3752.CrossRefGoogle ScholarPubMed
Barredo, JC, Devidas, M, Lauer, SJ, et al. Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study. J Clin Oncol 2006;24:3142–3149.CrossRefGoogle ScholarPubMed
Eapen, M, Zhang, MJ, Devidas, M, et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with acute lymphoblastic leukemia in a second remission after an isolated central nervous system relapse: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Leukemia 2008;22:281–286.CrossRefGoogle ScholarPubMed
Harker-Murray, PD, Thomas, AJ, Wagner, JE, et al. Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system. Biol Blood Marrow Transplant 2008;14:685–692.CrossRefGoogle ScholarPubMed
Bader, P, Kreyenberg, H, Henze, GH, et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol 2009;27:377–384.CrossRefGoogle ScholarPubMed
Raetz, EA, Borowitz, MJ, Devidas, M, et al. Reinduction platform for children with first marrow relapse in acute lymphoblastic lymphoma. J Clin Oncol 2008;26:3971–3978.CrossRefGoogle Scholar
Paganin, M, Zecca, M, Fabbri, G, et al. Minimal residual disease is an important predictive factor of outcome in children with relapsed ‘high-risk' acute lymphoblastic leukemia. Leukemia 2008;22:2193–2200.CrossRefGoogle ScholarPubMed
Bader, P, Kreyenberg, H, Hoelle, W, et al. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? J Clin Oncol 2004;22:1696–1705.CrossRefGoogle ScholarPubMed
Carpenter, PA, Snyder, DS, Flowers, ME, et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007;109:2791–2793.Google ScholarPubMed
Pulsipher, MA, Bader, P, Klingebiel, T, et al. Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse. Biol Blood Marrow Transplant 2008;15:62–71.CrossRefGoogle Scholar
Cooper, LJ.New approaches to allogeneic hematopoietic stem cell transplantation in pediatric cancers. Curr Oncol Rep 2009;11:423–430.CrossRefGoogle ScholarPubMed
Bosi, A, Laszlo, D, Labopin, M, et al. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2001;19:3675–3684.CrossRefGoogle Scholar
Michallet, M, Tanguy, ML, Socie, G, et al. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de moelle (SFGM). Br J Haematol 2000;108:400–407.CrossRefGoogle Scholar
Eapen, M, Giralt, SA, Horowitz, MM, et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant 2004;34:721–727.CrossRefGoogle ScholarPubMed
Oliansky, DM, Rizzo, JD, Aplan, PD, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review. Biol Blood Marrow Transplant 2007;13:1–25.CrossRefGoogle Scholar
Pession, A, Rondelli, R, Basso, G, et al. Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols. Leukemia 2005;19:2043–2053.CrossRefGoogle ScholarPubMed
Woods, WG, Neudorf, S, Gold, S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001;97:56–62.CrossRefGoogle ScholarPubMed
Lange, BJ, Smith, FO, Feusner, J, et al. Outcomes in CCG-2961, a Children's Oncology Group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Blood 2008;111:1044–1053.CrossRefGoogle ScholarPubMed
Ho, PA, Alonzo, TA, Gerbing, RB, et al. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood 2009;113:6558–6566.CrossRefGoogle ScholarPubMed
Brown, P, McIntyre, E, Rau, R, et al. The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood 2007;110:979–985.CrossRefGoogle ScholarPubMed
Balgobind, BV, Raimondi, SC, Harbott, J, et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood 2009;114:2489–2496.CrossRefGoogle ScholarPubMed
Hasle, H, Alonzo, TA, Auvrignon, A, et al. Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood 2007;109:4641–4647.CrossRefGoogle Scholar
Barbaric, D, Alonzo, TA, Gerbing, RB, et al. Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961. Blood 2007;109:2314–2321.CrossRefGoogle ScholarPubMed
Meshinchi, S, Alonzo, TA, Stirewalt, DL, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood 2006;108:3654–3661.CrossRefGoogle ScholarPubMed
Barnard, DR, Alonzo, TA, Gerbing, RB, et al. Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children's Oncology Group. Pediatr Blood Cancer 2007;49:17–22.CrossRefGoogle ScholarPubMed
Wells, RJ, Adams, MT, Alonzo, TA, et al. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. J Clin Oncol 2003;21:2940–2947.CrossRefGoogle ScholarPubMed
Alonzo, TA, Wells, RJ, Woods, WG, et al. Postremission therapy for children with acute myeloid leukemia: the children's cancer group experience in the transplant era. Leukemia 2005;19:965–970.CrossRefGoogle ScholarPubMed
Horan, JT, Alonzo, TA, Lyman, GH, et al. Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. J Clin Oncol 2008;26:5797–5801.CrossRefGoogle ScholarPubMed
Creutzig, U, Zimmermann, M, Ritter, J, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005;19:2030–2042.CrossRefGoogle ScholarPubMed
Ravindranath, Y, Yeager, AM, Chang, MN, et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med 1996;334:1428–1434.CrossRefGoogle ScholarPubMed
Godder, K, Eapen, M, Laver, JH, et al. Autologous hematopoietic stem-cell transplantation for children with acute myeloid leukemia in first or second complete remission: a prognostic factor analysis. J Clin Oncol 2004;22:3798–3804.CrossRefGoogle ScholarPubMed
MacMillan, ML, Davies, SM, Nelson, GO, et al. Twenty years of unrelated donor bone marrow transplantation for pediatric acute leukemia facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant 2008;14:16–22.CrossRefGoogle ScholarPubMed
Rubnitz, JE, Razzouk, BI, Lensing, S, et al. Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia. Cancer 2007;109:157–163.CrossRefGoogle ScholarPubMed
Bunin, NJ, Davies, SM, Aplenc, R, et al. Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy. J Clin Oncol 2008;26:4326–4332.CrossRefGoogle ScholarPubMed
Dvorak, CC, Agarwal, R, Dahl, GV, et al. Hematopoietic stem cell transplant for pediatric acute promyelocytic leukemia. Biol Blood Marrow Transplant 2008;14:824–830.CrossRefGoogle ScholarPubMed
Bierings, M, Nachman, JB, Zwaan, CM. Stem cell transplantation in pediatric leukemia and myelodysplasia: state of the art and current challenges. Curr Stem Cell Res Ther 2007;2:53–63.CrossRefGoogle ScholarPubMed
Woods, WG, Barnard, DR, Alonzo, TA, et al. Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group. J Clin Oncol 2002;20:434–440.Google ScholarPubMed
Yusuf, U, Frangoul, HA, Gooley, TA, et al. Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience. Bone Marrow Transplant 2004;33:805–814.CrossRefGoogle ScholarPubMed
Woodard, P, Barfield, R, Hale, G, et al. Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome. Pediatr Blood Cancer 2006;47:931–935.CrossRefGoogle ScholarPubMed
Venditti, A, Buccisano, F, Del, Poeta G, et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000;96:3948–3952.Google ScholarPubMed
Jacobsohn, DA, Tse, WT, Chaleff, S, et al. High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival. Br J Haematol 2009;146:669–674.CrossRefGoogle ScholarPubMed
Klyuchnikov, E, Schafhausen, P, Kroger, N, et al. Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. Acta Haematol 2009;122:6–10.CrossRefGoogle ScholarPubMed
Yee, KW, Zeng, Z, Konopleva, M, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006;12:5165–5173.CrossRefGoogle ScholarPubMed
Garcia-Manero, G, Kantarjian, HM, Sanchez-Gonzalez, B, et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 2006;108:3271–3279.CrossRefGoogle ScholarPubMed
Lubbert, M, Bertz, H, Wasch, R, et al. Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone Marrow Transplant 2010;45:627–632.CrossRefGoogle ScholarPubMed
Czibere, A, Bruns, I, Kroger, N, et al. 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Bone Marrow Transplant 2010;45:872–876.CrossRefGoogle ScholarPubMed
Leung, W.Immunotherapy in acute leukemia. Semin Hematol 2009;46:89–99.CrossRefGoogle ScholarPubMed
Levine, JE, Barrett, AJ, Zhang, MJ, et al. Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population. Bone Marrow Transplant 2008;42:201–205.CrossRefGoogle Scholar
Savani, BN, Mielke, S, Reddy, N, et al. Management of relapse after allo-SCT for AML and the role of second transplantation. Bone Marrow Transplant 2009;44:769–777.CrossRefGoogle ScholarPubMed
Meshinchi, S, Leisenring, WM, Carpenter, PA, et al. Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia. Biol Blood Marrow Transplant 2003;9:706–713.CrossRefGoogle ScholarPubMed
Stiff, PJ, Emmanouilides, C, Bensinger, WI, et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol 2006;24:5186–5193.CrossRefGoogle ScholarPubMed
Blazar, BR, Weisdorf, DJ, Defor, T, et al. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 2006;108:3216–3222.CrossRefGoogle Scholar
Robin, M, Marque-Juillet, S, Scieux, C, et al. Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcome. Haematologica 2007;92:1254–1257.CrossRefGoogle ScholarPubMed
Yusuf, U, Hale, GA, Carr, J, et al. Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. Transplantation 2006;81:1398–1404.CrossRefGoogle ScholarPubMed
Pavlakis, M, Haririan, A, Klassen, DK. BK virus infection after non-renal transplantation. Adv Exp Med Biol 2006;577:185–189.CrossRefGoogle ScholarPubMed
Ljungman, P, de la, Camara R, Cordonnier, C, et al. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant 2008;42:227–240.CrossRefGoogle ScholarPubMed
Gerritsen, EJ, Stam, ED, Hermans, J, et al. Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children. Bone Marrow Transplant 1996;18:377–382.Google ScholarPubMed
Shapiro, RS, McClain, K, Frizzera, G, et al. Epstein–Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988;71:1234–1243.Google ScholarPubMed
Brunstein, CG, Weisdorf, DJ, DeFor, T, et al. Marked increased risk of Epstein–Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006;108:2874–2880.CrossRefGoogle ScholarPubMed
Blaes, AH, Cao, Q, Wagner, JE, et al. Monitoring and preemptive rituximab therapy for Epstein–Barr virus reactivation after anti-thymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation. Biol Blood Marrow Transplant 2010;16:287–291.CrossRefGoogle ScholarPubMed
Kuehnle, I, Huls, MH, Liu, Z, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein–Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000;95:1502–1505.Google ScholarPubMed
Liu, Z, Savoldo, B, Huls, H, et al. Epstein–Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas. Recent Results Cancer Res 2002;159:123–133.CrossRefGoogle ScholarPubMed
Cutler, C, Henry, NL, Magee, C, et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005;11:551–557.CrossRefGoogle ScholarPubMed
Ho, VT, Cutler, C, Carter, S, et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005;11:571–575.CrossRefGoogle ScholarPubMed
Clark, JG, Hansen, JA, Hertz, MI, et al. NHLBI workshop summary. Idiopathic pneumonia syndrome after bone marrow transplantation. Am Rev Respir Dis 1993;147:1601–1606.CrossRefGoogle ScholarPubMed
Kantrow, SP, Hackman, RC, Boeckh, M, et al. Idiopathic pneumonia syndrome: changing spectrum of lung injury after marrow transplantation. Transplantation 1997;63:1079–1086.CrossRefGoogle ScholarPubMed
Yanik, GA, Ho, VT, Levine, JE, et al. The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Blood 2008;112:3073–3081.CrossRefGoogle ScholarPubMed
Reiss, U, Cowan, M, McMillan, A, et al. Hepatic venoocclusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients. J Pediatr Hematol Oncol 2002;24:746–750.CrossRefGoogle Scholar
Cesaro, S, Pillon, M, Talenti, E, et al. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Haematologica 2005;90:1396–1404.Google ScholarPubMed
Bearman, SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995;85:3005–3020.Google ScholarPubMed
Ruutu, T, Eriksson, B, Remes, K, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002;100:1977–1983.CrossRefGoogle ScholarPubMed
Richardson, PG, Murakami, C, Jin, Z, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002;100:4337–4343.CrossRefGoogle Scholar
Qureshi, A, Marshall, L, Lancaster, D. Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children. Pediatr Blood Cancer 2008;50:831–832.CrossRefGoogle ScholarPubMed
Glucksberg, H, Storb, R, Fefer, A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974;18:295–304.CrossRefGoogle ScholarPubMed
Leung, W, Ahn, H, Rose, SR, et al. A prospective cohort study of late sequelae of pediatric allogeneic hematopoietic stem cell transplantation. Medicine (Baltimore) 2007;86:215–224.CrossRefGoogle ScholarPubMed
Rizzo, JD, Curtis, RE, Socie, G, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009;113:1175–1183.CrossRefGoogle ScholarPubMed
Triplett, BM, Horwitz, EM, Iyengar, R, et al. Effects of activating NK cell receptor expression and NK cell reconstitution on the outcomes of unrelated donor hematopoietic cell transplantation for hematologic malignancies. Leukemia 2009;23:1278–1287.CrossRefGoogle ScholarPubMed
Shlomchik, WD, Lee, SJ, Couriel, D, et al. Transplantation's greatest challenges: advances in chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007;13:2–10.CrossRefGoogle ScholarPubMed
Bolanos-Meade, J, Vogelsang, GB. Chronic graft-versus-host disease. Curr Pharm Des 2008;14:1974–1986.CrossRefGoogle ScholarPubMed
Zecca, M, Prete, A, Rondelli, R, et al. Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood 2002;100:1192–1200.CrossRefGoogle Scholar
Filipovich, AH, Weisdorf, D, Pavletic, S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945–956.CrossRefGoogle ScholarPubMed
Shulman, HM, Kleiner, D, Lee, SJ, et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant 2006;12:31–47.CrossRefGoogle ScholarPubMed
Koc, S, Leisenring, W, Flowers, ME, et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 2002;100:48–51.CrossRefGoogle ScholarPubMed
Couriel, D, Carpenter, PA, Cutler, C, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease V. Ancillary Therapy and Supportive Care Working Group report. Biol Blood Marrow Transplant 2006;12:375–396.CrossRefGoogle ScholarPubMed
Pavletic, SZ, Martin, P, Lee, SJ, et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 2006;12:252–266.CrossRefGoogle ScholarPubMed
Imai, K, Matsuyama, S, Miyake, S, et al. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000;356:1795–1799.CrossRefGoogle ScholarPubMed
Hsu, KC, Keever-Taylor, CA, Wilton, A, et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005;105:4878–4884.CrossRefGoogle ScholarPubMed
Ruggeri, L, Capanni, M, Urbani, E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097–2100.CrossRefGoogle ScholarPubMed
Iyengar, R, Handgretinger, R, Babarin-Dorner, A, et al. Purification of human natural killer cells using a clinical-scale immunomagnetic method. Cytotherapy 2003;5:479–484.CrossRefGoogle ScholarPubMed
Leung, W, Iyengar, R, Leimig, T, et al. Phenotype and function of human natural killer cells purified by using a clinical-scale immunomagnetic method. Cancer Immunol Immunother 2005;54:389–394.CrossRefGoogle ScholarPubMed
Miller, JS, Soignier, Y, Panoskaltsis-Mortari, A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005;105:3051–3057.CrossRefGoogle ScholarPubMed
Passweg, JR, Tichelli, A, Meyer-Monard, S, et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 2004;18:1835–1838.CrossRefGoogle ScholarPubMed
Rubnitz, JE, Inaba, H, Ribeiro, RC, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010;28:955–959.CrossRefGoogle ScholarPubMed
Romagne, F, Andre, P, Spee, P, et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 2009;114:2667–2677.CrossRefGoogle ScholarPubMed
Imai, C, Iwamoto, S, Campana, D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005;106:376–383.CrossRefGoogle ScholarPubMed
Fujisaki, H, Kakuda, H, Shimasaki, N, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009;69:4010–4017.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×